These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 19027348)

  • 1. Seeking alternative biological therapies: the future of targeted molecular treatment.
    Lorch JH; Posner MR; Wirth LJ; Haddad RI
    Oral Oncol; 2009; 45(4-5):447-53. PubMed ID: 19027348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
    Harrington KJ; Kazi R; Bhide SA; Newbold K; Nutting CM
    Indian J Cancer; 2010; 47(3):248-59. PubMed ID: 20587899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
    Gilbert J; Argiris A
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor directed therapy in head and neck cancer.
    Choong NW; Cohen EE
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
    Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular-targeted therapies in head and neck cancer.
    Rao SD; Fury MG; Pfister DG
    Semin Radiat Oncol; 2012 Jul; 22(3):207-13. PubMed ID: 22687945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
    Lau PC; Chan AT
    Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.
    Langer CJ
    Cancer; 2008 Jun; 112(12):2635-45. PubMed ID: 18442098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in squamous cell carcinoma of the head and neck.
    Gold KA; Lee HY; Kim ES
    Cancer; 2009 Mar; 115(5):922-35. PubMed ID: 19156911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).
    Hambek M; Baghi M; Baumaun H; Strebhardt K; Adunka O; Gstöttner W; Knecht R
    Anticancer Res; 2005; 25(3B):1871-5. PubMed ID: 16158919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE
    J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy.
    Machiels JP; Schmitz S
    Curr Opin Oncol; 2011 May; 23(3):241-8. PubMed ID: 21358328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New advances in targeted therapies for squamous cell carcinoma of the head and neck.
    Machiels JP; Schmitz S
    Anticancer Drugs; 2011 Aug; 22(7):626-33. PubMed ID: 21048493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for squamous-cell carcinoma of the head and neck.
    Papaspyrou G; Werner JA; Dietz A
    Expert Opin Pharmacother; 2011 Feb; 12(3):397-409. PubMed ID: 21254947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.
    Matta A; Ralhan R
    Head Neck Oncol; 2009 Mar; 1():6. PubMed ID: 19284526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.